Thyroid-Stimulating Immunoglobulins

1982 ◽  
Vol 16 (5) ◽  
pp. 317-328 ◽  
Author(s):  
A. Pinchera ◽  
G.F. Fenzi ◽  
E. Macchia ◽  
L. Bartalena ◽  
S. Mariotti ◽  
...  
Keyword(s):  
Thyroid Stimulating Immunoglobulins

Thyroid Stimulating Immunoglobulins: Measurement and Clinical use

1985 ◽  
Vol 69 (2) ◽  
pp. 113-121 ◽  
Author(s):  
C. A. Ollis ◽  
S. Tomlinson ◽  
D. S. Munro
Keyword(s):  
Thyroid Hormones ◽  
Elevated Serum ◽  
Serum Levels ◽  
The Other ◽  
Graves Disease ◽  
Clinical Use ◽  
Hormone Production ◽  
Skin Changes ◽  
Thyroid Stimulating Immunoglobulins ◽  
Eye Involvement

Graves’ disease is the commonest form of hyperthyroidism in which excessive production of thyroid hormones by the hyperplastic overactive thyroid gland produces elevated serum levels of the thyroid hormones tri-iodothyronine (T3) and thyroxine (T4). Many of the manifestations of Graves’ disease, increased basal metabolic rate, increased heart rate, heat intolerance, sweating and nervousness, can be attributed to the peripheral actions of the excess thyroid hormones. The pathogenesis of many of the other dramatic features of Graves’ disease, such as the eye involvement or localized skin changes, is not fully understood, but circulating immunoglobulins with thyroid stimulating activity are almost certainly linked to excess thyroid hormone production and thereby cause the hyperthyroidism.

scholarly journals Thyroid-stimulating immunoglobulins in neonatal Graves's disease.

1980 ◽  
Vol 55 (11) ◽  
pp. 894-895 ◽  
Author(s):  
C S Teng ◽  
T C Tong ◽  
J H Hutchison ◽  
R T Yeung
Keyword(s):  
Thyroid Stimulating Immunoglobulins

scholarly journals Detection of Thyroid-Stimulating Immunoglobulins by Use of Enzyme-Fragment Complementation

2008 ◽  
Vol 54 (8) ◽  
pp. 1401-1402 ◽  
Author(s):  
Tanya Sandrock ◽  
Alan Terry ◽  
Jeff C Martin ◽  
Evrim Erdogan ◽  
Wayne A Meikle
Keyword(s):  
Thyroid Stimulating Immunoglobulins ◽  
Fragment Complementation

Changes in Thyroid-Stimulating Immunoglobulins during Antithyroid Therapy*

1979 ◽  
Vol 48 (4) ◽  
pp. 572-576 ◽  
Author(s):  
GIANFRANCO FENZI ◽  
KIYOSHI HASHIZUME ◽  
CORBIN P. ROUDEBUSH ◽  
LESLIE J. DEGROOT
Keyword(s):  
Antithyroid Therapy ◽  
Thyroid Stimulating Immunoglobulins

scholarly journals MASSIVE THYMIC HYPERPLASIA SECONDARY TO GRAVES DISEASE

2020 ◽  
Vol 6 (3) ◽  
pp. e144-e146
Author(s):  
WingYee Wan ◽  
Jeffrey A. Colburn
Keyword(s):  
Computed Tomography ◽  
Thyroid Stimulating Hormone ◽  
Free Thyroxine ◽  
Thymic Hyperplasia ◽  
Anterior Mediastinal Mass ◽  
Graves Disease ◽  
Presenting Symptoms ◽  
Thyroid Stimulating Immunoglobulins ◽  
Computed Tomography Angiogram ◽  
Stimulating Hormone

Objective: Graves disease (GD) has a well-known association with thymic hyperplasia, which is seen histo-logically in up to 38% of patients with GD. However, there have only been approximately 100 documented cases of Graves-associated massive thymic hyperplasia. Potential mechanisms of thymic pathology are reviewed. Methods: A 24-year-old female presented to the emergency department with dyspnea, palpitations, tachycardia, anxiety, and weight loss. She was evaluated for hyperthyroidism using labs (thyroid-stimulating hormone, free thyroxine, thyroid-stimulating immunoglobulins) and imaging (radioactive iodine uptake [RAIU] scan), leading to treatment with radioiodine. A computed tomography angiogram of the chest was also performed to evaluate for pulmonary embolism given the patient's presenting symptoms. Results: Our patient was found to have undetectable thyroid-stimulating hormone, elevated free thyroxine (2.9 ng/dL), and elevated thyroid-stimulating immunoglobulins (399%). Diagnosis of GD was confirmed on RAIU scan. The computed tomography chest angiogram demonstrated a significant anterior mediastinal mass (7.9 × 6.9 × 6.3 cm). Treatment with radioiodine led to reduction of the mass by 76% in volume. Conclusion: While the patient's thyroid labs and RAIU scan were consistent with GD, the presence of massive thymic hyperplasia was atypical. However, the resolution of thymic hyperplasia after radioiodine therapy, without the use of thymectomy, was similar to other reported cases.

Ciclosporin and thyroid-stimulating immunoglobulins in endocrine orbitopathy

1989 ◽  
Vol 189 (5) ◽  
pp. 355-362 ◽  
Author(s):  
G. Kahaly ◽  
J. P. Yuan ◽  
U. Krause ◽  
K. Hülbusch ◽  
J. Beyer
Keyword(s):  
Endocrine Orbitopathy ◽  
Thyroid Stimulating Immunoglobulins

A comparison of porcine and human thyroid tissue in the assay of thyroid stimulating immunoglobulins

1986 ◽  
Vol 113 (3) ◽  
pp. 335-339
Author(s):  
S. de Rave ◽  
H. M.J. Goldschmidt ◽  
Y. T.J. Somers-Pijnenburg ◽  
B. Bravenboer ◽  
J. H. M. Lockefeer
Keyword(s):  
Medical Treatment ◽  
Thyroid Tissue ◽  
Human Thyroid ◽  
Graves Disease ◽  
Clinical Use ◽  
Human Thyroid Tissue ◽  
Thyroid Stimulating Immunoglobulins ◽  
Camp Generation

Abstract. The central role of Thyroid Stimulating Immunoglobulins (TSI) in the pathogenesis of the hyperthyroidism of Graves' disease has become generally accepted and a wide variety of assays for the detection of these antibodies has been developed. The dependence on the availability of human thyroid tissue makes most of these assays unsuitable for routine clinical use, a problem circumvented by the use of nonhuman thyroid tissue in some TSI assays. We therefore compared porcine and human thyroid tissue in a TSI assay based on in vitro cAMP generation. No major differences in within and between run variation were found and, with some notable exceptions, a reasonable correlation could be demonstrated between the results in both assays (R = 0.89, P < 0.001). However, the sensitivity of the porcine TSI assay is only 60% of the estimated sensitivity of the human TSI assay. In spite of the practical advantages this porcine TSI assay, and possibly also other TSI assays using non-human thyroid tissue, cannot totally replace human TSI assays. The value of these assays in predicting the outcome of medical treatment of Graves' disease remains to be established.

Sign in / Sign up

Export Citation Format

Share Document